

2014
Press release



www.genfit.com

GFT505: NEW PATENTS ALLOWED IN THE UNITED STATES AND CHINA

- **After the recent grant of a European patent for GFT505 in NASH and hepatic fibrosis, GENFIT strengthens the intellectual property around GFT505 in the United States and in China.**

Lille (France), Boston (Massachusetts, United States), October 17, 2014

– GENFIT (Euronext: GNFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions in metabolic and inflammatory diseases, that notably affect the liver or the gastrointestinal system, today announces the allowance in China of a patent for GFT505, its leading drug candidate, in NASH and hepatic fibrosis. Moreover, after the grant of an American patent for GFT505 in NASH, the USPTO has allowed the patent in hepatic fibrosis.

With the grant of the new patents, GFT505 will be protected in these major markets up to the end of 2035, via the usual patent extension clauses.

These patents protect the use of GFT505 not only in NASH, but also in other hepatic diseases.

The new patents bring the total number of GENFIT's international patents to 364, of which 299 cover GFT505.

Jean-François Mouney, Chairman and Chief Executive Officer of GENFIT, declared: *«These new patents strengthen the territorial position of GFT505, notably in China. In addition to NASH, they now cover hepatic fibrosis. This marks the high medical potential of our drug candidate, and is perfectly in line with our industrial and commercial development strategy».*

About GENFIT:

GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in fields of high medical need due to a lack of suitable treatment and an increasing number of patients worldwide. GENFIT's R&D efforts are focused on contributing to bringing new medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver (such as NASH - Nonalcoholic steatohepatitis) or the bowel (such as the inflammatory bowel disease). GENFIT implements mutually beneficial approaches that combine novel treatments and biomarkers; its research programs have resulted in the creation of a rich and diversified pipeline of drug candidates, including GENFIT's lead proprietary compound, GFT505, that is completing a Phase 2b study in NASH.

With facilities in Lille, France, and Boston, MA (USA), the Company has approximately 80 employees. GENFIT is a public company listed in compartment B of Euronext's regulated market in Paris (Euronext: GNFT; ISIN: FR0004163111). www.genfit.com

Disclaimer:

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Listing Prospectus upon the admission of Company's shares for trading on the regulated market Euronext of Euronext Paris filed with the AMF, which is available on the AMF website (www.amf-france.org) or on GENFIT's website (www.genfit.com).

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in GENFIT in any country.

Contacts

GENFIT | Jean-François Mouney - CEO & Chairman of the Management Board | Ph. +333 2016 4000

MILESTONES – Relation Presse | Bruno Arabian | Ph. +331 8362 3484 / +336 8788 4726 – barabian@milestones.fr